Blood Transfusion Supplement 4 - Plasma-derived medicinal products: demand and clinical use (off subscription) (September)
Clinical use and the Italian demand for prothrombin complex concentrates
 
Authors:  Massimo Franchini, Giancarlo M. Liumbruno, Monica Lanzoni, Fabio Candura, Stefania Vaglio, Samantha Profili, Giuseppina Facco, Gabriele Calizzani, Giuliano Grazzini
Pages:  94-100
To cite this article:  Blood Transfus 2013; 11 Suppl 4: s94-100
Doi:  10.2450/2013.015s
Published online:  08/10/2013

Preview
Introduction
Prothrombin complex concentrates (PCCs) are an important plasma-derived therapeutic option for the rapid correction of deficiency of vitamin-K dependent clotting factors1. PCCs are produced by ion-exchange chromatography from the cryoprecipitate supernatant of large plasma pools after removal of antithrombin and factor (F) XI2. Different processing techniques involving ion exchangers permit the production of either three- (i.e., FII, FIX and FX) or four-factor (i.e., FII, FVII, FIX and FX) concentrates with a final overall clotting factor concentration approximately 25 times higher than in normal plasma (Tables I and II)3. To prevent activation of these factors, most PCCs contain heparin. In addition, they may also contain the physiological inhibitors of coagulation protein C and protein S. PCCs are standardised according to their FIX content and are subjected to viral inactivation processes, both by physical (vapour, heating) and chemical (solvent detergent treatment) methods. (...)
  
Full Text Download Back
       
Share this article: